Skip to main content
Premium Trial:

Request an Annual Quote

Affibody and NCI to Develop Molecular In Vivo Imaging Agents

NEW YORK, Nov. 8 (GenomeWeb News) - Affibody and the National Cancer Institute plan to co-develop conjugates with Affibody molecules to be used for in vivo imaging, the Swedish company said today.


The agreement combines Affibody's internally developed technology with the US National Institute of Health's conjugation systems.


Affibody will develop engineered Affibody molecules specific for HER2, a receptor protein sometimes over-expressed in breast and ovarian cancers. NCI will conjugate the engineered molecules with detection molecules for evaluation.


Additional details were not disclosed.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.